Protagonist Therapeutics, a spin-out company from The University of Queensland’s Institute for Molecular Bioscience (IMB), has raised $40 million to begin clinical trials of an oral drug for Inflammatory Bowel Disease.
Queensland researchers are one step closer to printing 3D human kidney tissue thanks to a partnership between The University of Queensland and a US biotechnology company.